Pence awards $3.5M contract to anti-abortion charity group
Gov. Mike Pence cited the successes of a $1 million pilot program as reason for granting a new $3.5 million contract to Real Alternatives, a Pennsylvania-based charity.
Gov. Mike Pence cited the successes of a $1 million pilot program as reason for granting a new $3.5 million contract to Real Alternatives, a Pennsylvania-based charity.
Long-time health care executive Charles C. Miraglia was picked by the center’s board of directors to replace interim CEO Dan A. Waxman, who has been in that position since January.
William S. Gibbons Jr., Cook's vice president of of global engineering, and his 15-year-old daughter, Abbey, were killed when the plane crashed into Buffalo Mountain in eastern Tennessee.
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Suzhou, China-based Innovent could receive payments totaling more than $1 billion if the cancer products it develops with Lilly reach certain milestones.
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.
Dr. Malaz Boustani leads a 26-person team at Eskenazi Health that is showing the group's approach to health care can improve the mental health of both dementia patients and their care givers.
Five months after it expected to hold an election, the union trying to organize nurses at Indiana University Health’s downtown hospitals doesn’t even have a projected date for a vote.
Researchers at the Indiana University School of Medicine think they have found a way to predict possible suicides using blood tests and questionnaires on tablet computers.
Health care providers say they can’t attract patients tomorrow with facilities from yesterday. So they are scrambling to erect new structures that are more convenient.
Puerto Rico officials are looking to replace an expiring tax with a new levy to draw much-needed revenue from the world’s best-selling medications while seeking to avoid driving U.S. manufacturers such as Eli Lilly and Co. from the commonwealth.
The university will lead a consortium of eight institutions that will use the money to create a system of coaches embedded in medical practices.
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
With the number of applications to Marian’s College of Osteopathic Medicine running twice as high as initially expected, school leaders say they are confident Marian can help reduce a looming physician shortage in Indiana.
The new college's academic programs would include athletic training, nursing, speech pathology and psychology.
An Indiana not-for-profit has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90 percent after re-acquiring rights to the medicine from Rodelis Therapeutics.
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Pharmaceutical industry members are likely to dislike the proposal, which would require them disclose how much they spend on research and development, production, and sales and marketing.
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.